ALX Oncology Q1 2026 Results

ALX Oncology Q1 2026 Results
ALX Oncology Holdings reported its first quarter 2026 financial results during an earnings call on May 8. The biopharmaceutical company, led by CEO Jason Lettmann, discussed progress on its clinical pipeline and operational developments. Key focus areas included advancement of oncology programs and financial positioning as the company continues to develop innovative cancer treatments. Investors and analysts reviewed the company's performance metrics and strategic initiatives for the remainder of 2026.